2-imidazolines Patents (Class 514/401)
-
Publication number: 20120231061Abstract: This invention is related to the use of polyurethane-based polymer as a drug delivery device to deliver biologically active compounds at a constant rate for an extended period of time and methods of manufactures thereof. The device is very biocompatible and biostable, and is useful as an implant in patients (humans and animals) for the delivery of appropriate bioactive substances to tissues or organs.Type: ApplicationFiled: March 9, 2012Publication date: September 13, 2012Inventors: Petr KUZMA, Harry QUANDT
-
Publication number: 20120225918Abstract: Provided are pharmaceutical compositions, and methods of use of the compositions, for the non-surgical treatment of ptosis (eyelid droop). In one embodiment the composition includes oxymetazoline 0.1% formulated for topical administration to an eye. In one embodiment the composition includes a synergistic combination of oxymetazoline and phenylephrine, formulated for topical administration to an eye. Oxymetazoline alone causes no pupillary dilation (mydriasis), and a synergistic combination of oxymetazoline and phenylephrine induces no clinically significant mydriasis. In addition to providing desirable cosmetic effects, the compositions and methods of the invention can improve visual fields otherwise compromised by ptosis.Type: ApplicationFiled: August 26, 2011Publication date: September 6, 2012Applicant: VOOM, LLCInventor: Mark Silverberg
-
Publication number: 20120225919Abstract: Provided are pharmaceutical compositions, and methods of use of the compositions, for the non-surgical treatment of ptosis (eyelid droop). In one embodiment the composition includes oxymetazoline 0.1% formulated for topical administration to an eye. In one embodiment the composition includes a synergistic combination of oxymetazoline and phenylephrine, formulated for topical administration to an eye. Oxymetazoline alone causes no pupillary dilation (mydriasis), and a synergistic combination of oxymetazoline and phenylephrine induces no clinically significant mydriasis. In addition to providing desirable cosmetic effects, the compositions and methods of the invention can improve visual fields otherwise compromised by ptosis.Type: ApplicationFiled: October 11, 2011Publication date: September 6, 2012Applicant: VOOM, LLCInventor: Mark Silverberg
-
Publication number: 20120225920Abstract: Provided are pharmaceutical compositions, and methods of use of the compositions, for the non-surgical treatment of ptosis (eyelid droop). In one embodiment the composition includes oxymetazoline 0.1% formulated for topical administration to an eye. In one embodiment the composition includes a synergistic combination of oxymetazoline and phenylephrine, formulated for topical administration to an eye. Oxymetazoline alone causes no pupillary dilation (mydriasis), and a synergistic combination of oxymetazoline and phenylephrine induces no clinically significant mydriasis. In addition to providing desirable cosmetic effects, the compositions and methods of the invention can improve visual fields otherwise compromised by ptosis.Type: ApplicationFiled: February 29, 2012Publication date: September 6, 2012Applicant: VOOM, LLCInventor: Mark Silverberg
-
Publication number: 20120225827Abstract: Compositions, products and methods including silicone based excipients are provided. The compositions, products and methods of the present invention are particularly useful for the treatment of ophthalmic diseases.Type: ApplicationFiled: March 2, 2012Publication date: September 6, 2012Inventors: Kevin S. Warner, Ajay Parashar
-
Publication number: 20120178757Abstract: A method is provided for the prevention of cancer metastasis in a patient comprising administering an adrenergic receptor antagonist to a patient in need thereof. The invention also includes an adrenergic receptor antagonist for use in the prevention of tumour recurrence in a patient. Also provided is a kit of parts for use in such methods comprising an adrenergic receptor antagonist, and an administration vehicle. A method is further included for identifying a patient at risk of developing cancer comprising the step of assaying for levels of expression of adrenergic receptor genes and proteins in said patient.Type: ApplicationFiled: December 8, 2011Publication date: July 12, 2012Applicant: NOTTINGHAM UNIVERSITY HOSPITALS NHS TRUSTInventor: Desmond George Powe
-
Publication number: 20120177585Abstract: Embodiments of the present invention are directed to compositions and methods for the treatment of purpura. Preferred compositions comprise an ? adrenergic receptor agonist selected from selective ?1 adrenergic receptor agonist, selective ?2 adrenergic receptor agonist, non-selective ?1/?2 adrenergic receptor agonist, agents with ?2 adrenergic receptor agonist activity and combinations thereof, in a pharmaceutically acceptable carrier in order to treat and improve the cosmetic appearance of hemorrhagic (purpuric) lesions in the skin.Type: ApplicationFiled: January 6, 2012Publication date: July 12, 2012Applicant: ALLERGAN, INC.Inventors: Stuart D. Shanler, Andrew Ondo
-
Publication number: 20120149748Abstract: The present invention provides pharmaceutical cream compositions comprising oxymetazoline and methods for treating rosacea and other skin disorders as described herein using the above cream compositions.Type: ApplicationFiled: December 1, 2011Publication date: June 14, 2012Applicant: ALLERGAN, INC.Inventors: Stuart D. Shanler, Christopher Powala, Luis Rios
-
Publication number: 20120142747Abstract: Effective treatments of pain for extended periods of time are provided. Through the administration of an effective amount of immediate release clonidine and a sustained release clonidine at or near a target site, one can relieve pain caused by diverse sources, including but not limited to spinal disc herniation (i.e. sciatica), spondilothesis, stenosis, discogenic back pain and joint pain. When appropriate formulations are provided within biodegradable polymers, this relief can be continued for at least three days. In some embodiments, the relief can be for at least twenty-five days, at least fifty days, at least one hundred days, at least one hundred and thirty-five days or at least one hundred and eighty days or longer.Type: ApplicationFiled: December 2, 2011Publication date: June 7, 2012Applicant: Warsaw Orthopedic, Inc.Inventors: Jared T. Wilsey, Danielle L. Biggs, Jonathan K. Gray, Jeffrey C. Marx, William F. McKay, Josee Roy, John Myers Zanella
-
Publication number: 20120142643Abstract: Effective treatments of pain for extended periods of time are provided. Through the administration of an effective amount of clonidine and a gamma-aminobutyric acid compound at or near a target site, one can relieve pain caused by diverse sources, including but not limited to spinal disc herniation (i.e. sciatica), spondilothesis, stenosis, discogenic back pain and joint pain, as well as pain that is incidental to surgery. When appropriate formulations are provided within biodegradable polymers, this relief can be continued for at least three days. In some embodiments, the relief can be for at least twenty-five days, at least fifty days, at least one hundred days, at least one hundred and thirty-five days or at least one hundred and eighty days.Type: ApplicationFiled: December 2, 2011Publication date: June 7, 2012Applicant: Warsaw Orthopedic, Inc.Inventors: Jared T. Wilsey, Danielle L. Biggs, Jeffrey C. Marx, William F. McKay, Josee Roy, John Myers Zanella
-
Publication number: 20120128763Abstract: A formulation has been developed for treatment of the symptoms of dry eye which incorporates the natural product jojoba wax, or components thereof, to enhance the spreading of the artificial tear and eyedrop as well as stabilize the eyedrop. The improved performance of the jojoba wax supplemented tear relieves irritation and discomfort as well as sharpens the blurred vision.Type: ApplicationFiled: February 2, 2012Publication date: May 24, 2012Inventor: Steven Maskin
-
Publication number: 20120101141Abstract: Improved topical gel compositions for the treatment of skin disorders are described. The gel compositions contain carbomer and methylparaben, and are substantially free of methylparaben crystalline particles after an extended period of storage.Type: ApplicationFiled: September 22, 2011Publication date: April 26, 2012Applicant: GALDERMA R&D SNC.Inventors: Jean-Christophe BUGE, Karine NADAU-FOURCADE, Cyril MEUNIER
-
Patent number: 8163725Abstract: Improved topical gel compositions for the treatment of skin disorders are described. The gel compositions contain carbomer and methylparaben, and are substantially free of methylparaben crystalline particles after an extended period of storage.Type: GrantFiled: September 22, 2011Date of Patent: April 24, 2012Assignee: Galderma R&D SNCInventors: Jean-Christophe Buge, Karine Nadau-Fourcade, Cyril Meunier
-
Publication number: 20120083508Abstract: Disclosed herein is a pharmaceutical composition comprising a pain-relieving anticonvulsant and an alpha-2B receptor agonist. The composition is effective for treating chronic pain, and methods of treating chronic pain using the composition and the compounds comprising it are also disclosed.Type: ApplicationFiled: November 14, 2011Publication date: April 5, 2012Applicant: ALLERGAN, INC.Inventors: Daniel W. Gil, John E. Donello
-
Publication number: 20120070467Abstract: The present invention includes and provides a method of delivering a medicament to an eye of a subject in need thereof a solution, the method comprising: (a) providing droplets containing the medicament with a specified average size and average initial ejecting velocity; and (b) delivering the medicament to the eye, where the droplets deliver a percentage of the ejected mass of the droplets to the eye.Type: ApplicationFiled: July 15, 2011Publication date: March 22, 2012Applicant: Corinthian Ophthalmic, Inc.Inventors: Bernard L. Ballou, JR., Mark Packer, Russell John Mumper, Tsontcho Inachulev
-
Publication number: 20120071506Abstract: The present invention relates to a method for treating a disorder selected from depression, anxiety disorders, bipolar disorder, attention deficit hyperactivity disorder, stress-related disorders, psychotic disorders such as schizophrenia, neurological diseases such as Parkinson's disease, neurodegenerative disorders such as Alzheimer's disease, epilepsy, migraine, hypertension, substance abuse and metabolic disorders such as eating disorders, diabetes, diabetic complications, obesity, dyslipidemia, disorders of energy consumption and assimilation, disorders and malfunction of body temperature homeostasis, disorders of sleep and circadian rhythm, and cardiovascular disorders which comprises administering to an individual a therapeutically effective amount of a compound of formula I wherein R1, R2, Q, W, X, Y, m, and n are as defined in the specification, and their pharmaceutically active salts, racemic mixtures, enantiomers, optical isomers and tautomeric forms.Type: ApplicationFiled: November 23, 2011Publication date: March 22, 2012Inventors: Guido Galley, Katrin Groebke Zbinden, Roger Norcross, Henri Stalder
-
Publication number: 20120058056Abstract: This invention concerns a method of treating hemangiomas with a beta blocker by applying the beta blocker onto the hemangiomas directly. The invention also concerns a combination therapy by using a beta blocker along with a corticosteroid or an alpha adrenergic receptor agonist for the treatment of hemangiomas.Type: ApplicationFiled: April 9, 2010Publication date: March 8, 2012Applicant: UNIVERSITY OF MEDICINE AND DENTISTRY OF NEW JERSEYInventor: Suqin Guo
-
Publication number: 20120039960Abstract: The present invention relates to tetracaine based anesthetic formulations and methods of use thereof. The invention further relates to topical formulations of tetracaine and methods of topically anesthetizing body tissues. The present invention also relates to tetracaine based dental anesthetic formulations and methods for anesthetizing the maxillary dental arch using these formulations.Type: ApplicationFiled: April 2, 2010Publication date: February 16, 2012Applicant: ST. RENATUS, LLCInventor: Mark David Kollar
-
Publication number: 20120041031Abstract: Disclosed herein is a method of upregulating regulatory T-cells, and treating diseases that would benefit from such upregulation, by administering an alpha 2 receptor agonist.Type: ApplicationFiled: August 11, 2011Publication date: February 16, 2012Applicant: ALLERGAN, INCInventors: Daniel W. Gil, John E. Donello, Veena Viswanath, Lauren M.B. Luhrs
-
Publication number: 20120035123Abstract: A combination of compounds for treating skin diseases and particularly rosacea and ocular rosacea is described. The combination of a compound of the avermectin family or of the mylbemycin family with a compound of the family of the alpha-1 or alpha-2 adrenergic receptor agonists is also described. In addition, a product in the form of a kit including: (a) a first composition containing a compound of the avermectin family or of the mylbemycin family, and (b) a second composition different from the first one and containing a compound of the family of the alpha-1 or alpha-2 adrenergic receptor agonists, as a combination product to be used as a drug for treating and/or preventing skin diseases and particularly rosacea and ocular rosacea, wherein said first and second compositions can be applied simultaneously, separately or with a time delay is described.Type: ApplicationFiled: February 16, 2010Publication date: February 9, 2012Applicant: Galderma Research & DevelopmentInventors: André Jomard, Laurent Fredon, Olivier Roye
-
Publication number: 20120035235Abstract: Described herein are compounds for and methods of treating conditions or diseases in a subject by administering to the subject a pharmaceutical composition containing an effective amount of an ?-adrenergic modulator. The compounds and methods are also useful for alleviating types of pain, both acute and chronic.Type: ApplicationFiled: October 17, 2011Publication date: February 9, 2012Applicant: ALLERGAN, INC.Inventors: Wenkui K. Fang, Phong X. Nguyen, Ken Chow, Todd M. Heidelbaugh, Dario G. Gomez, Michael E. Garst, Santosh C. Sinha, Daniel W. Gil, John E. Donello
-
Publication number: 20120029042Abstract: The present invention is directed to a method for treating osteolytic bone cancer. The method comprises implanting a drug depot locally at or near the osteolytic bone cancer, wherein the drug depot comprises at least one biodegradable polymer and clonidine in an amount from about 0.1 wt. % to about 30 wt. % of the drug depot.Type: ApplicationFiled: July 30, 2010Publication date: February 2, 2012Applicant: WARSAW ORTHOPEDIC, INC.Inventor: Vanja Margareta King
-
Publication number: 20120021072Abstract: The invention features topical formulations comprising an osmotically active agent and/or a vasoconstrictor and/or an astringent agent for the treatment and prevention of eyelid swelling, and methods of use thereof.Type: ApplicationFiled: September 21, 2011Publication date: January 26, 2012Applicant: Aciex Therapeutics, Inc.Inventors: Matthew Jonathan Chapin, Mark Barry Abelson, Keith Jeffrey Lane, Akimitsu Makino
-
Publication number: 20120010125Abstract: Compounds and pharmaceutical compositions containing such compounds having formula I are provided: where R1, R2a, R2b, R3, R4, and R5 are as defined herein. The compounds and pharmaceutical compositions thereof are useful for the prevention and treatment of a variety of conditions in mammals including humans, including anxiety and mood disorders such as depression.Type: ApplicationFiled: April 19, 2011Publication date: January 12, 2012Inventors: Eric A. Stone, Yan Lin, David Quartermain, Yasmeen Sarfraz
-
Patent number: 8071636Abstract: Described herein are compounds for and methods of treating conditions or diseases in a subject by administering to the subject a pharmaceutical composition containing an effective amount of an ?-adrenergic modulator. The compounds and methods are also useful for alleviating types of pain, both acute and chronic.Type: GrantFiled: June 5, 2009Date of Patent: December 6, 2011Assignee: Allergan, Inc.Inventors: Wenkui K. Fang, Phong X. Nguyen, Ken Chow, Todd M. Heidelbaugh, Dario G. Gomez, Michael E. Garst, Santosh C. Sinha, Daniel W. Gil, John E. Donello
-
Publication number: 20110288096Abstract: Methods and products for treating or preventing erythema or a symptom associated with erythema in a subject are described. The methods involve topically applying to an affected skin area a topical aqueous gel composition comprising about 0.01% to about 10% by weight of at least one ?-adrenergic receptor agonist and a pharmaceutically acceptable carrier.Type: ApplicationFiled: March 25, 2011Publication date: November 24, 2011Applicant: GALDERMA LABORATORIES INC.Inventors: Michael GRAEBER, Christian LOESCHE, Philip FREIDENREICH, Jack A. DEJOVIN, Isabelle Jean DEJOVIN, Yin-Sang LIU, Matthew J. LEONI
-
Publication number: 20110288140Abstract: The present invention concerns a pharmaceutical composition comprising an alpha-2 adrenergic receptor agonist for preventing or treating inflammatory pain and diseases in mucosa of oral cavity, pharynx and larynx. Inanother aspect the present invention provides mucosal bioadhesive slow release carriers for the extended and controlled release of alpha-2 adrenergic receptor agonists that can be used on mucosal surfaces for preventing or treating inflammatory pain and diseases in mucosa of oral cavity.Type: ApplicationFiled: September 17, 2009Publication date: November 24, 2011Applicant: BIOALLIANCE PHARMA ,S.A.Inventors: Pierre Attali, Caroline Lemarchand, Vanessa Roulet, Claire Scheuir, Lorraine Zakin
-
Publication number: 20110286945Abstract: Methods, compounds, and topical formulations for reduction of skin sagging, creasing and/or wrinkling are disclosed. The methods comprise topically applying a composition comprising an ?2 adrenergic receptor agonist. Amelioration of skin sagging, creasing and/or wrinkling begins within minutes after topical application of a disclosed composition. A single application can significantly reduce skin sagging, creasing and/or wrinkling for at least about 8 hours.Type: ApplicationFiled: August 2, 2011Publication date: November 24, 2011Applicant: GALDERMA LABORATORIES INC.Inventors: Jack DeJovin, Isabelle Jean DeJovin
-
Patent number: 8053427Abstract: Improved topical gel compositions, such as those containing brimonidine, for the treatment of skin disorders are described. The gel compositions contain carbomer and methylparaben, and are substantially free of methylparaben crystalline particles after an extended period of storage.Type: GrantFiled: June 13, 2011Date of Patent: November 8, 2011Assignee: Galderma R&D SNCInventors: Jean-Christophe Buge, Karine Nadau-Fourcade, Cyril Meunier
-
Publication number: 20110245314Abstract: A composition and method of treating adrenergic dysregulation by administering the composition is disclosed, wherein the composition comprises a ?2-adrenergic receptor agonist; a pharmaceutically acceptable hydrophilic matrix and a release-retardant of a metal alkyl sulfate. In embodiments, the composition provides a sustained release of the agonist, wherein after administration of the composition no more than once about every 12 hours to a subject having a steady state plasma concentration of the ?2-adrenergic receptor agonist, the agonist's plasma concentration peak-to-trough ratio is no greater than about 1.9.Type: ApplicationFiled: April 8, 2011Publication date: October 6, 2011Inventors: Henry Joseph Horacek, Min Michael He, Moise A. Khayrallah
-
Publication number: 20110237639Abstract: This invention relates to an alpha-1 A receptor partial agonist, which is represented by Formula I: and pharmaceutically acceptable salts or solvates thereof. The invention further relates to pharmaceutical compositions containing formula I, methods for their use as therapeutic agents, and methods of preparation thereof.Type: ApplicationFiled: June 3, 2011Publication date: September 29, 2011Inventors: Counde O'Yang, Dennis Mitsugu Yasuda
-
Publication number: 20110230535Abstract: This invention relates to an alpha-1A receptor partial agonist, which is represented by Formula I: and pharmaceutically acceptable salts or solvates thereof. The invention further relates to pharmaceutical compositions containing formula I, methods for their use as therapeutic agents, and methods of preparation thereof.Type: ApplicationFiled: June 3, 2011Publication date: September 22, 2011Inventors: Counde O'Yang, Robert Greenhouse
-
Publication number: 20110218223Abstract: Vasoconstrictors are administered topically to provide protection against the adverse effects, e.g., alopecia, mucositis or dermatitis, induced by chemotherapy or radiotherapy. Appropriate dosages and formulations of topical vasoconstrictors are provided. Methods for the use of such compositions are also provided.Type: ApplicationFiled: May 12, 2011Publication date: September 8, 2011Inventors: William E. Fahl, Arnold E. Ruoho, Minesh Mehta
-
Publication number: 20110195974Abstract: A method of treating inflammation and joint deterioration in mammals includes administering a therapeutically effective dose of alpha 1A receptor antagonists alone or in combination with a beta 2 adrenergic antagonists or beta 2 adrenergic antagonists and beta 2 adrenergic agonists.Type: ApplicationFiled: August 25, 2008Publication date: August 11, 2011Inventor: Rekha Bansal
-
Publication number: 20110182849Abstract: Effective compositions and methods for treating an intervertebral disc are provided. The compositions and methods comprise a bulking agent or sealing agent, the bulking agent or sealing agent adapted to be administered at or within the intervertebral disc, the bulking or sealing agent having a drug depot comprising an effective amount of a therapeutic agent disposed therein, wherein the drug depot is capable of releasing an effective amount of the therapeutic agent over a period of at least one day.Type: ApplicationFiled: January 28, 2010Publication date: July 28, 2011Applicant: WARSAW ORTHOPEDIC, INC.Inventors: Sean M. Haddock, Susan J. Drapeau, Thomas Andrew Simonton
-
Publication number: 20110182857Abstract: Liquid pharmaceutical compositions for administration to a mucosal surface, including a therapeutic agent and a pectin with a low degree of esterification are described. Such compositions gel, or can be adapted to gel, at the site of application in the absence of an extraneous source of divalent metal ions.Type: ApplicationFiled: April 1, 2011Publication date: July 28, 2011Applicant: ARCHIMEDES DEVELOPMENT LIMITEDInventors: Peter James WATTS, Lisbeth ILLUM
-
Publication number: 20110184037Abstract: Effective methods of treating back pain from an intervertebral disc are provided. The methods of treatment include administering an immediate release analgesic at or near the intervertebral disc; administering a bulking agent or sealing agent within the intervertebral disc; and administering a sustained release analgesic within the intervertebral disc, wherein the sustained release analgesic releases the analgesic over a period of at least one day.Type: ApplicationFiled: January 28, 2010Publication date: July 28, 2011Applicant: WARSAW ORTHOPEDIC, INC.Inventors: Sean M. Haddock, Susan J. Drapeau, Thomas Andrew Simonton
-
Publication number: 20110178147Abstract: The disclosure provides a composition for controlling pupil dilation comprising about 0.001% to about 1.0% by weight of an alpha-adrenergic receptor antagonist selected from phentolamine, phentolamine mesylate, or a phentolamine salt; and at least one excipient selected from the group consisting of a buffer, tonicity agent, preservative, antioxidant, surfactant, solubilizer, cosolvent, and a combination thereof. A method of controlling pupil dilation in a subject in need thereof, comprising administering a therapeutically effective amount of the composition is also provided.Type: ApplicationFiled: October 19, 2010Publication date: July 21, 2011Applicant: ALLERGAN, INC.Inventors: Sukhon Likitlersuang, Ajay P. Parashar, Chetan Pujara
-
Patent number: 7981899Abstract: Disclosed are the use of compatible solutes for inhibiting the release of ceramides or for the prophylaxis and protection of human skin against premature skin aging and for the prophylaxis and protection of human skin against wrinkling.Type: GrantFiled: March 3, 2003Date of Patent: July 19, 2011Assignee: Merck Patent GmbHInventors: Joachim Bünger, Jean Krutmann
-
HYDROGEL COMPOSITIONS COMPRISING VASOCONSTRICTING AND ANTI-HEMORRHAGIC AGENTS FOR DERMATOLOGICAL USE
Publication number: 20110171310Abstract: The present specification generally relates to hydrogel compositions and methods of treating a soft tissue condition using such hydrogel compositions.Type: ApplicationFiled: November 30, 2010Publication date: July 14, 2011Applicant: ALLERGAN INDUSTRIE, SASInventors: Cecile Gousse, Pierre F. Lebreton, Nicolas Prost -
Publication number: 20110171311Abstract: The present specification generally relates to hydrogel compositions and methods of treating a soft tissue condition using such hydrogel compositions.Type: ApplicationFiled: January 13, 2011Publication date: July 14, 2011Applicant: ALLERGAN INDUSTRIE, SASInventors: Cecile GOUSSE, Pierre F. LEBRETON, Nicolas PROST
-
Publication number: 20110160268Abstract: The present invention relates to methods of treating subjects with alveolar capillary membrane injury or methods of preventing alveolar capillary membrane injury in subjects, with the methods comprising administering to the subjects a therapeutically effective amount of ergothioneine and a pharmaceutically acceptable carrier. The invention also relates to methods of screening candidate compounds for their ability to mitigate the effects of alveolar capillary membrane injury.Type: ApplicationFiled: June 22, 2009Publication date: June 30, 2011Inventor: John E. Repine
-
Publication number: 20110160267Abstract: A method for treating diabetic retinopathy involving topically administering to an eye of a patient a pharmacologically effective amount of a compound represented by the following formula [II] or a salt thereof: wherein R1, R2 and R3 are the same or different and represent a hydrogen atom or an alkyl group, or R1 and R3 may be joined together to form a ring having one or more double bonds.Type: ApplicationFiled: March 4, 2011Publication date: June 30, 2011Applicant: SANTEN PHARMACEUTICAL CO., LTD.Inventors: Kouji Oohashi, Reina Doi, Tatsuji Kurose, Masaaki Kageyama
-
Publication number: 20110160195Abstract: A method and solution for perioperatively inhibiting a variety of pain and inflammation processes during arthroscopic procedures. The solution preferably includes a vasoconstrictor that exhibits alpha-adrenergic activity and one or more additional pain and inflammation inhibitory agents at dilute concentration in a physiologic carrier, such as saline or lactated Ringer's solution. The solution is applied by continuous irrigation of a wound during a surgical procedure for peripheral vasoconstriction and inhibition of pain and/or inflammation while avoiding undesirable side effects associated with systemic application of larger doses of the agents.Type: ApplicationFiled: March 14, 2011Publication date: June 30, 2011Inventors: Gregory A. Demopulos, Pamela Pierce Palmer, Jeffrey M. Herz
-
Publication number: 20110152274Abstract: This application relates to the use of one or more parasympathomimetic drugs in combination with one or more alpha agonists to create optically beneficial miosis to, for example, temporarily treat presbyopia. The invention provides a pharmaceutical preparation comprising a therapeutically effective amount of one or more parasympathomimetic drugs or cholinesterase inhibitors, or a pharmaceutically acceptable salt thereof, in combination with one or more alpha agonists or antagonists, or a pharmaceutically acceptable salt thereof. The invention further provides for a method for treating, ameliorating or reducing presbyopia of a patient having an eye, comprising administering to said eye a pharmaceutically effective amount of the ophthalmic preparation.Type: ApplicationFiled: December 20, 2010Publication date: June 23, 2011Inventor: Herbert E. KAUFMAN
-
Publication number: 20110152271Abstract: The invention provides compositions and methods for treating nasal congestion through ophthalmic delivery. The provided compositions and methods utilize low concentrations of selective ?-2 adrenergic receptor agonists. The compositions preferably include brimonidine.Type: ApplicationFiled: December 17, 2010Publication date: June 23, 2011Inventor: Gerald Horn
-
Publication number: 20110136884Abstract: The invention provides methods for treating disorders associated with selective subtype modulation of alpha 2 adrenergic receptors. In particular, the invention provides methods employing well-defined N-[1-(2 and/or 3-substituted-phenyl)-alkyl]-(4,5-dihydro-1H-imidazol-2-yl)-amines and pharmaceutical compositions thereof to treat disorders associated with selective subtype alpha 2 adrenergic receptor modulation, such as ocular disorders, pain and central nervous system (CNS) motor disorders.Type: ApplicationFiled: May 11, 2009Publication date: June 9, 2011Applicant: ALLERGAN, INC.Inventors: Phong X. Nguyen, Ken Chow, Todd M. Heidelbaugh
-
Publication number: 20110118267Abstract: Methods and kits for treating or preventing psoriasis or a symptom associated with psoriasis in a subject are described. The methods involve topical applications to the subject a therapeutically effective amount of an ?2 adrenergic receptor agonist, such as brimonidine.Type: ApplicationFiled: November 19, 2009Publication date: May 19, 2011Applicant: Galderma Laboratories, L.P.Inventor: Jack A. DeJovin
-
Publication number: 20110104155Abstract: A method and means for delivery of drugs to the chorio-retina and the optic nerve head which comprises contacting the surface of the eye with an effective amount of drug for treatment of chorio-retina and optic nerve head and a physiologically acceptable adrenergic agent for enhancing delivery of the drug to these tissues in an ophtalmologically acceptable carrier, said adrenergic agent being selected from the group consisting of alpha adrenergic agonist agents, derivatives of the alpha adrenergic agonist agents, beta-blocking agents, derivatives of the beta-blocking agents and mixtures thereof.Type: ApplicationFiled: May 5, 2008Publication date: May 5, 2011Applicant: Raouf RekikInventor: Raouf Rekik
-
Publication number: 20110097393Abstract: This invention relates to a sustained release oral and transdermal pharmaceutical formulations and delivery systems comprising lofexidine. The invention is also directed to methods of treatment comprising administering lofexidine in a sustained release manner. Such methods can involve administration of the lofexidine containing compositions described herein. Compositions of lofexidine formulated for sustained release delivery are provided. Also provided are methods for the treatment of opiate addicts, migraine, neuropathic pain, and other therapeutic indications related to lofexidine. The methods may provide treatment for a variety of conditions amenable to amelioration by lofexidine administration. The methods utilize lofexidine compositions formulated for transdermal and sustained release oral delivery for administration of lofexidine in an amount effective for the treatment of the drug indications.Type: ApplicationFiled: June 25, 2009Publication date: April 28, 2011Applicant: US WorldMeade, LLCInventor: Abeer M. Al-Ghananeem